A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: JNJ-73763989Drug: Tenofovir disoproxilDrug: Tenofovir alafenamide (TAF)Drug: Entecavir (ETV) monohydrateDrug: PegIFN-alpha2a
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT04667104
- Locations
- π―π΅
Tokyo Medical and Dental University Hospital, Bunkyo Ku, Japan
π―π΅Osaka University Hospital, Suita-shi, Japan
π΅π±Przychodnia EuroMediCare Wroclaw Lowiecka, Wroclaw, Poland
A Study to Compare Two Different Subcutaneously-administered JNJ-64304500 Formulations in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: JNJ 64304500
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 43
- Registration Number
- NCT04667052
- Locations
- πΊπΈ
WCCT Global, LLC, Cypress, California, United States
A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat as Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared With Co-administration of the Separate Agents
- Conditions
- Healthy
- Interventions
- Drug: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDCDrug: DarunavirDrug: Emtricitabine/Tenofovir AlafenamideDrug: Cobicistat
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 37
- Registration Number
- NCT04661397
- Locations
- π³π±
PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen, Netherlands
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- Biological: CetrelimabDrug: CisplatinDrug: TAR-200Drug: GemcitabineRadiation: Conventional radiation therapyRadiation: Hypo-fractioned radiation therapy
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 518
- Registration Number
- NCT04658862
- Locations
- πΊπΈ
University of Southern California, Los Angeles, California, United States
π¦π·Centro Oncologico Riojano Integral (Cori), La Rioja, Argentina
π§π·Fundacao Pio XII, Barretos, Brazil
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
- Conditions
- Lymphoma, Non-HodgkinChronic Lymphocytic Leukemia
- Interventions
- Drug: JNJ-64264681Drug: JNJ-67856633
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 75
- Registration Number
- NCT04657224
- Locations
- πΊπΈ
Stony Brook University Medical Center, Stony Brook, New York, United States
π¦πΊMonash Medical Centre, Clayton, Australia
π¦πΊPeter MacCallum Cancer Centre, Melbourne, Australia
A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease
- Conditions
- Crohn Disease
- Interventions
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT04655807
- Locations
- πΊπΈ
Medisphere Medical Research Center, Llc, Evansville, Indiana, United States
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
- Conditions
- Prostatic NeoplasmsAdenocarcinoma
- Interventions
- Drug: JNJ-69086420
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 231
- Registration Number
- NCT04644770
- Locations
- πΊπΈ
XCancer Omaha / Urology Cancer Center, Omaha, Nebraska, United States
πΊπΈCase Western Reserve University, Cleveland, Ohio, United States
πΊπΈMemorial Sloan Kettering Cancer Center, New York, New York, United States
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-GuΓ©rin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- Drug: TAR-200Biological: Cetrelimab
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 220
- Registration Number
- NCT04640623
- Locations
- πΊπΈ
Urological Associates of Southern Arizona, P.C., Tucson, Arizona, United States
πΊπΈUniversity of Southern California, Los Angeles, California, United States
πΊπΈGenesis Healthcare Partners - Genesis Research Greater Los Angeles, Sherman Oaks, California, United States
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 480
- Registration Number
- NCT04634552
- Locations
- πΊπΈ
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
π΅π±Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut BadawczyOddz w Gliwicach, Gliwice, Poland
πΊπΈUniversity of Alabama Birmingham, Birmingham, Alabama, United States
A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 53
- Registration Number
- NCT04633447
- Locations
- πͺπΈ
Hosp Regional Univ de Malaga, Malaga, Spain
πͺπΈHosp Univ A Coruna, A Coruna, Spain
πΊπΈUniversity of Kansas Medical Center, Kansas City, Kansas, United States